Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

STAA

Staar Surgical Co.

Sep 06 • 04:00PM ET

31.12

Dollar change -0.08
Percentage change -0.26	%

Healthcare • Medical Instruments & Supplies • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: IJR VTI VB IWM VXF VBK IWO SPSM IJT VTWO

Index	RUT	P/E	92.90	EPS (ttm)	0.34	Insider Own	0.82%	Shs Outstand	48.84M	Perf Week	-3.17%
Market Cap	1.53B	Forward P/E	39.30	EPS next Y	0.79	Insider Trans	0.77%	Shs Float	48.78M	Perf Month	-14.39%
Income	16.61M	PEG	3.10	EPS next Q	0.19	Inst Own	96.42%	Short Float	8.02%	Perf Quarter	-23.10%
Sales	332.94M	P/S	4.60	EPS this Y	-27.67%	Inst Trans	2.11%	Short Ratio	5.25	Perf Half Y	-11.36%
Book/sh	8.32	P/B	3.74	EPS next Y	8.40%	ROA	3.49%	Short Interest	3.91M	Perf Year	-24.67%
Cash/sh	4.78	P/C	6.51	EPS next 5Y	30.00%	ROE	4.36%	52W Range	26.66 - 52.68	Perf YTD	-0.29%
Dividend Est.	-	P/FCF	112.97	EPS past 5Y	31.51%	ROI	3.77%	52W High	-40.93%	Beta	0.60
Dividend TTM	-	Quick Ratio	5.21	Sales past 5Y	21.55%	Gross Margin	79.24%	52W Low	16.75%	ATR (14)	1.82
Dividend Ex-Date	-	Current Ratio	5.80	EPS Y/Y TTM	-34.15%	Oper. Margin	7.90%	RSI (14)	32.65	Volatility	3.95% 5.34%
Employees	1115	Debt/Eq	0.09	Sales Y/Y TTM	8.83%	Profit Margin	4.99%	Recom	1.93	Target Price	50.28
Option/Short	Yes / Yes	LT Debt/Eq	0.08	EPS Q/Q	20.90%	Payout	0.00%	Rel Volume	1.03	Prev Close	31.20
Sales Surprise	3.98%	EPS Surprise	63.25%	Sales Q/Q	7.26%	Earnings	Aug 07 AMC	Avg Volume	744.55K	Price	31.12
SMA20	-10.84%	SMA50	-21.57%	SMA200	-17.33%	Trades		Volume	769,669	Change	-0.26%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-15-24	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$50 → $37
Jun-11-24	Upgrade	BTIG Research	Neutral → Buy	$46
Mar-11-24	Upgrade	Stifel	Hold → Buy	$30 → $50
Dec-05-23	Downgrade	Needham	Buy → Hold
Dec-04-23	Initiated	Morgan Stanley	Equal-Weight	$35
Sep-15-23	Downgrade	The Benchmark Company	Buy → Hold
Aug-03-23	Downgrade	Canaccord Genuity	Buy → Hold	$77 → $48
Jun-07-23	Downgrade	William Blair	Outperform → Mkt Perform
Apr-17-23	Initiated	Piper Sandler	Neutral	$65
Feb-06-23	Downgrade	BTIG Research	Buy → Neutral
Dec-28-22	Reiterated	BTIG Research	Buy	$80 → $67
Dec-08-22	Initiated	Stifel	Hold	$60
Nov-07-22	Upgrade	Sidoti	Neutral → Buy
Oct-14-22	Resumed	Stephens	Overweight	$91
Oct-13-22	Initiated	Mizuho	Buy	$85
Apr-08-22	Initiated	Needham	Buy	$87
Mar-28-22	Upgrade	The Benchmark Company	Hold → Buy	$97
Mar-18-22	Upgrade	BTIG Research	Neutral → Buy	$98
Jul-09-21	Initiated	Oppenheimer	Perform	$150
Jan-19-21	Downgrade	The Benchmark Company	Buy → Hold

Show Previous Ratings

Sep-06-24 01:01PM	Baillie Gifford Reduces Stake in Staar Surgical Co (GuruFocus.com)
Aug-13-24 10:48AM	Implied Volatility Surging for STAAR Surgical (STAA) Stock Options (Zacks)
Aug-12-24 09:15AM	Why Staar Surgical (STAA) International Revenue Trends Deserve Your Attention (Zacks)
Aug-07-24 11:53PM	STAA Stock Earnings: Staar Surgical Misses EPS, Beats Revenue for Q2 2024 (InvestorPlace) +11.03%
08:00PM	Staar Surgical (STAA) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
05:20PM	Loading…
05:20PM	Staar Surgical (STAA) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
04:22PM	Staar Surgical: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	STAAR Surgical Reports Second Quarter 2024 Results (Business Wire)
Jul-31-24 07:00AM	STAAR Surgical to Report Second Quarter Results on August 7, 2024 (Business Wire)
Jul-30-24 07:00AM	STAAR Surgical to Participate in Canaccord Genuity 44th Annual Growth Conference (Business Wire)
Jun-27-24 01:25PM	Staar Surgical Stock Earns RS Rating Upgrade (Investor's Business Daily)
04:01AM	Staar Surgical (STAA) Soars 7.5%: Is Further Upside Left in the Stock? (Zacks)
Jun-05-24 07:00AM	STAAR Surgical to Participate in Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-13-24 11:06AM	Don't Overlook Staar Surgical (STAA) International Revenue Trends While Assessing the Stock (Zacks)
May-08-24 11:06AM	STAAR Surgical Company (NASDAQ:STAA) Q1 2024 Earnings Call Transcript (Insider Monkey) -12.07%
10:17AM	Loading…
10:17AM	Mizuho Adjusts STAAR Surgical's Price Target to $55 From $53, Keeps Buy Rating (MT Newswires)
07:59AM	Morgan Stanley Raises Price Target on STAAR Surgical to $50 From $35, Keeps Equalweight Rating (MT Newswires)
03:43AM	Staar Surgical Co (STAA) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth Amid ... (GuruFocus.com)
May-07-24 11:54PM	STAA Stock Earnings: Staar Surgical Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:30PM	Staar Surgical (STAA) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:58PM	Staar Surgical Co Reports Q1 2024 Results: Misses Earnings Projections Despite Revenue Growth (GuruFocus.com)
05:26PM	Staar Surgical: Q1 Earnings Snapshot (Associated Press Finance)
04:03PM	STAAR Surgical Reports First Quarter 2024 Results (Business Wire)
04:01PM	STAAR Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision (Business Wire)
May-06-24 09:16AM	Wall Street's Insights Into Key Metrics Ahead of Staar Surgical (STAA) Q1 Earnings (Zacks)
May-01-24 07:00AM	STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel (Business Wire)
Apr-29-24 07:00AM	STAAR Surgical to Report First Quarter Results on May 7, 2024 (Business Wire)
Apr-25-24 03:43PM	Staar Surgical Stock Climbs The Leadership Ladder With Jump To 84 RS Rating (Investor's Business Daily)
Apr-05-24 09:15AM	Strength Seen in Staar Surgical (STAA): Can Its 16.5% Jump Turn into More Strength? (Zacks) +6.97%
Apr-04-24 04:26PM	Staar Surgical, A Lasik Rival, Just Crushed Quarterly Views; But Is Its 2026 Target Too Aggressive? (Investor's Business Daily) +16.48%
03:54PM	Loading…
03:54PM	Eye Lens Maker STAAR Surgical Expects Q1 Sales To Beat Consensus (Benzinga)
07:00AM	STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024 (Business Wire)
Apr-02-24 07:00AM	STAAR Surgical Celebrates Three Million Lens Milestone at ASCRS Meeting, Unveils New EVO ICL Data and Latest Innovation for 2024 (Business Wire)
Mar-26-24 11:45AM	Nvidias Market Cap Myopia: 3 Stocks Proving Size Isnt Everything (InvestorPlace)
Mar-20-24 04:22AM	STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses (PR Newswire)
Mar-18-24 07:00AM	STAAR Surgical Celebrates Three Million Implantable Collamer Lenses (Business Wire)
Mar-12-24 10:30AM	Sidoti Events, LLC's Virtual March Small-Cap Conference (ACCESSWIRE)
07:00AM	STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors (Business Wire)
Mar-06-24 07:00AM	STAAR Surgical to Participate in Two Upcoming Investor Conferences (Business Wire) +6.67%
Feb-28-24 10:58AM	STAAR Surgical Company (NASDAQ:STAA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 02:00PM	Staar Surgical (STAA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
Feb-26-24 05:30PM	Staar Surgical (STAA) Beats Q4 Earnings Estimates (Zacks)
04:39PM	Staar Surgical: Q4 Earnings Snapshot (Associated Press Finance)
04:34PM	Staar Surgical Co (STAA) Posts Solid Growth in Q4 and FY 2023, Affirms Positive Outlook for 2024 (GuruFocus.com)
04:01PM	STAAR Surgical Reports Fourth Quarter and Fiscal Year 2023 Results (Business Wire)
Feb-19-24 07:00AM	STAAR Surgical to Report Fourth Quarter Results on February 26, 2024 (Business Wire)
Jan-27-24 01:03PM	Baillie Gifford Adjusts Position in Staar Surgical Co (GuruFocus.com)
Jan-23-24 07:00AM	STAAR Surgical Announces Strategic Agreement in U.S. with SharpeVision (Business Wire)
Jan-12-24 06:49PM	Howard Hughes, Carrier, and More Stocks See Action From Activist Investors (Barrons.com) -5.14%
Jan-08-24 07:00AM	STAAR Surgical Announces Preliminary Results for Fourth Quarter and Fiscal 2023 (Business Wire) +11.52%
Dec-17-23 12:35PM	7 Stocks with Strong Insider Buying: December 2023 (InvestorPlace)
Dec-05-23 03:16AM	Lululemon Athletica gets one more downgrade ahead of Q3 report: 4 big analyst cuts (Investing.com)
Dec-04-23 04:05PM	Lilian Zhou Appointed to STAAR Surgical Board of Directors (Business Wire)
Nov-15-23 07:00AM	STAAR Surgical to Present at Stephens Annual Investment Conference (NASH2023) (Business Wire)
Nov-02-23 05:50PM	STAAR Surgical Company (NASDAQ:STAA) Q3 2023 Earnings Call Transcript (Insider Monkey) -16.87%
09:23AM	Q3 2023 STAAR Surgical Co Earnings Call (Thomson Reuters StreetEvents)
Nov-01-23 06:30PM	Here's What Key Metrics Tell Us About Staar Surgical (STAA) Q3 Earnings (Zacks)
05:56PM	Staar Surgical Co (STAA) Reports 6% Y/Y Increase in Q3 2023 Net Sales (GuruFocus.com)
04:17PM	Staar Surgical: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	STAAR Surgical Reports Third Quarter 2023 Results (Business Wire)
Oct-31-23 04:40PM	Investor urges STAAR Surgical to spin off Asia unit - letter (Reuters)
Oct-18-23 04:05PM	STAAR Surgical to Report Third Quarter Results on November 1, 2023 (Business Wire)
Oct-17-23 07:00AM	STAAR Surgical Celebrates 30th Anniversary of Implantable Collamer Lens (ICL) (Business Wire)
Oct-13-23 06:30PM	Staar Surgical, Howard Hughes Holdings, and More Stocks See Action From Activist Investors (Barrons.com) +6.01%
Oct-10-23 10:51AM	Jimmy O. Yang Partners with STAAR Surgical to Shine a Light on Their Vision Correction Lens, EVO ICL (PR Newswire)
Sep-19-23 11:51AM	Is Staar Surgical Co (STAA) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap (GuruFocus.com)
Sep-15-23 09:32AM	Shake Shack upgraded, DoorDash downgraded: Wall Street's top analyst calls (The Fly)
Sep-14-23 12:53PM	Is Staar Surgical Co (STAA) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap (GuruFocus.com)
07:00AM	STAAR Surgical to Ring Nasdaq Stock Market Closing Bell Following Vision 2026 Investor Day on September 14, 2023 (Business Wire)
Sep-08-23 11:38AM	Staar Surgical Co (STAA): A Potential Value Trap? (GuruFocus.com)
Sep-07-23 05:00PM	STAAR Surgical to Host "Vision 2026" Investor Day on September 14, 2023 (Business Wire)
Aug-18-23 10:40AM	Dolby Labs jumps as S&P prepares to add it to its MidCap 400 index (Investing.com)
Aug-17-23 06:48PM	Dolby Laboratories Set to Join S&P MidCap 400; Staar Surgical to Join S&P SmallCap 600 (PR Newswire)
Aug-09-23 07:00AM	STAAR Surgical Teams Up With Tennessee Titans Quarterback Will Levis On Life Changing Vision Correction Procedure, EVO ICL (Business Wire)
Aug-07-23 07:00AM	STAAR Surgical to Participate in Upcoming Investor Conferences (Business Wire)
05:00AM	3 Strong Buy Growth Stocks You Should Be Loading Up On Now (InvestorPlace)
Aug-03-23 07:18PM	Why STAAR Surgical Stock Dropped Today (Motley Fool) -9.60%
Aug-02-23 05:25PM	Staar Surgical (STAA) Q2 Earnings Beat Estimates (Zacks)
04:21PM	Staar Surgical: Q2 Earnings Snapshot (AP Finance)
04:01PM	STAAR Surgical Reports Second Quarter 2023 Results (Business Wire)
Jul-19-23 07:00AM	STAAR Surgical to Report Second Quarter Results on August 2, 2023 (Business Wire)
Jun-21-23 08:00PM	STAA: Rating increased to a HOLD (Argus Research)
Jun-13-23 08:00AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
May-26-23 06:00AM	STAAR Surgical Company (NASDAQ:STAA) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? (Simply Wall St.)
May-17-23 10:10AM	2 Stocks With Unstoppable Growth Potential for the Next Decade (Motley Fool)
May-09-23 01:48PM	STAAR Surgical (NASDAQ:STAA) Shareholders Will Want The ROCE Trajectory To Continue (Simply Wall St.)
May-04-23 07:00AM	EVO ICL Sponsors Jonas Brothers The Tour (Business Wire) -7.78%
May-03-23 05:35PM	Staar Surgical (STAA) Beats Q1 Earnings and Revenue Estimates (Zacks)
04:29PM	Staar Surgical: Q1 Earnings Snapshot (AP Finance)
04:01PM	STAAR Surgical Reports First Quarter 2023 Results (Business Wire)
Apr-27-23 10:02AM	Cardinal Health (CAH) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Apr-26-23 08:00PM	STAA: Lowering target price to $54.00 (Argus Research)
10:02AM	Earnings Preview: Staar Surgical (STAA) Q1 Earnings Expected to Decline (Zacks)
Apr-23-23 08:25AM	Should You Think About Buying STAAR Surgical Company (NASDAQ:STAA) Now? (Simply Wall St.)
Apr-19-23 07:00AM	STAAR Surgical to Report First Quarter Results on May 3, 2023 (Business Wire)
Apr-07-23 11:44AM	STAAR Surgical's (NASDAQ:STAA) investors will be pleased with their incredible 346% return over the last five years (Simply Wall St.)
Apr-04-23 06:00PM	Staar Surgical (STAA) Gains As Market Dips: What You Should Know (Zacks)
Mar-29-23 06:00PM	Staar Surgical (STAA) Stock Sinks As Market Gains: What You Should Know (Zacks)
07:00AM	STAAR Surgical Names Warren Foust Chief Operating Officer; Magda Michna, Ph.D., Chief Clinical, Regulatory and Medical Affairs Officer (Business Wire)
Mar-23-23 06:00PM	Staar Surgical (STAA) Outpaces Stock Market Gains: What You Should Know (Zacks)

STAAR Surgical Co. engages in the design, development, manufacture, and sale of ophthalmic surgical products. The firm offers implantable lenses for the eye and accessory delivery systems. Its products include refractive and cataract solutions through the Collamer brand. The company was founded in 1982 and is headquartered in Lake Forest, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Butcher Arthur C	Director	Aug 12 '24	Buy	37.99	1,315	49,957	4,208	Aug 19 05:31 PM
BROADWOOD PARTNERS, L.P.	10% Owner	May 09 '24	Buy	42.56	1	43	10,768,431	May 13 06:00 PM
WEISNER AIMEE S	Director	Mar 14 '24	Buy	38.11	1,750	66,692	10,864	Mar 14 05:23 PM
Williams Patrick F.	Chief Financial Officer	Mar 07 '24	Option Exercise	0.00	2,614	0	45,475	Mar 11 06:06 AM
BROADWOOD PARTNERS, L.P.	10% Owner	Jan 08 '24	Buy	27.11	4,042	109,570	10,768,430	Jan 10 05:44 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Jan 05 '24	Buy	28.48	156,734	4,463,231	10,764,388	Jan 05 07:07 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Jan 04 '24	Buy	28.91	63,246	1,828,183	10,607,654	Jan 05 07:07 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Jan 03 '24	Buy	28.93	6,573	190,144	10,544,408	Jan 05 07:07 PM
Zhou Lilian Yansheng	Director	Dec 06 '23	Buy	30.74	850	26,129	2,327	Dec 06 04:11 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Nov 30 '23	Buy	31.42	177,707	5,583,678	10,537,835	Nov 30 07:08 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Nov 29 '23	Buy	31.39	160,300	5,031,358	10,360,128	Nov 30 07:08 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Nov 28 '23	Buy	31.85	96,984	3,088,794	10,199,828	Nov 30 07:08 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Nov 10 '23	Buy	32.73	34,320	1,123,383	10,102,337	Nov 14 07:13 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Nov 13 '23	Buy	33.04	507	16,749	10,102,844	Nov 14 07:13 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Nov 08 '23	Buy	33.71	139,409	4,699,073	9,928,017	Nov 09 07:01 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Nov 09 '23	Buy	33.09	140,000	4,632,581	10,068,017	Nov 09 07:01 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Nov 07 '23	Buy	34.03	9,731	331,127	9,788,608	Nov 09 07:01 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Nov 06 '23	Buy	34.16	164,607	5,623,518	9,778,877	Nov 06 07:01 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Nov 02 '23	Buy	35.79	144,027	5,155,243	9,613,750	Nov 06 07:01 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Nov 03 '23	Buy	36.06	520	18,753	9,614,270	Nov 06 07:01 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Oct 05 '23	Buy	37.92	97,474	3,696,399	9,394,424	Oct 06 07:43 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Oct 06 '23	Buy	37.62	75,299	2,832,417	9,469,723	Oct 06 07:43 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Oct 04 '23	Buy	37.93	32,523	1,233,649	9,296,950	Oct 06 07:43 PM
Lin Elizabeth Yeu	Director	Sep 21 '23	Buy	40.00	2,500	100,000	2,855	Sep 22 07:18 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Sep 21 '23	Buy	39.62	154,814	6,133,467	9,264,427	Sep 21 08:31 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Sep 20 '23	Buy	40.67	132,079	5,372,274	9,109,613	Sep 21 08:31 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Sep 19 '23	Buy	40.89	4,490	183,613	8,977,534	Sep 21 08:31 PM

Open in Screener

OCX

Oncocyte Corporation

Sep 06 • 04:00PM ET

3.19

Dollar change +0.14
Percentage change 4.59	%

Healthcare • Diagnostics & Research • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

OCX Oncocyte Corporation daily Stock Chart

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-4.26	Insider Own	11.32%	Shs Outstand	13.37M	Perf Week	1.51%
Market Cap	42.65M	Forward P/E	-	EPS next Y	-1.83	Insider Trans	162.36%	Shs Float	11.86M	Perf Month	6.33%
Income	-36.80M	PEG	-	EPS next Q	-0.46	Inst Own	53.61%	Short Float	1.71%	Perf Quarter	16.00%
Sales	1.02M	P/S	41.81	EPS this Y	39.07%	Inst Trans	-23.98%	Short Ratio	5.80	Perf Half Y	6.33%
Book/sh	1.70	P/B	1.88	EPS next Y	19.91%	ROA	-44.55%	Short Interest	0.20M	Perf Year	-5.34%
Cash/sh	0.69	P/C	4.61	EPS next 5Y	-	ROE	-101.76%	52W Range	2.08 - 4.34	Perf YTD	27.60%
Dividend Est.	-	P/FCF	-	EPS past 5Y	14.72%	ROI	-145.23%	52W High	-26.50%	Beta	1.00
Dividend TTM	-	Quick Ratio	1.38	Sales past 5Y	16.25%	Gross Margin	-96.14%	52W Low	53.37%	ATR (14)	0.20
Dividend Ex-Date	-	Current Ratio	1.38	EPS Y/Y TTM	67.49%	Oper. Margin	-2115.74%	RSI (14)	53.93	Volatility	5.21% 6.71%
Employees	46	Debt/Eq	0.16	Sales Y/Y TTM	-	Profit Margin	-3597.65%	Recom	2.00	Target Price	4.12
Option/Short	No / Yes	LT Debt/Eq	0.12	EPS Q/Q	98.33%	Payout	-	Rel Volume	0.19	Prev Close	3.05
Sales Surprise	-67.36%	EPS Surprise	31.29%	Sales Q/Q	-77.54%	Earnings	Aug 08 AMC	Avg Volume	35.03K	Price	3.19
SMA20	3.28%	SMA50	2.89%	SMA200	5.44%	Trades		Volume	6,676	Change	4.59%

Date	Action	Analyst	Rating Change	Price Target Change
May-24-22	Downgrade	Stephens	Overweight → Equal-Weight
Mar-14-22	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Jan-07-22	Initiated	Stephens	Overweight	$3.10
Jan-06-22	Resumed	Piper Sandler	Overweight	$3.10
Mar-17-21	Resumed	Needham	Buy	$8
Jan-07-21	Upgrade	The Benchmark Company	Speculative Buy → Buy	$6
Dec-16-20	Upgrade	Piper Sandler	Neutral → Overweight	$2 → $4
Nov-30-20	Initiated	BTIG Research	Buy	$5
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$5
Jul-30-20	Reiterated	The Benchmark Company	Speculative Buy	$7 → $6
Jul-01-20	Downgrade	Piper Sandler	Overweight → Neutral
Jun-30-20	Downgrade	Chardan Capital Markets	Buy → Neutral	$2
Jun-02-20	Initiated	Needham	Buy	$4
Feb-13-19	Initiated	Piper Jaffray	Overweight	$6
Jan-29-19	Upgrade	Janney	Neutral → Buy
Dec-19-18	Resumed	Lake Street	Buy

Show Previous Ratings

Aug-20-24 09:00AM	PRISM MarketView Features Oncocyte CFO Andrea S. James on Her Career and Leadership in Molecular Diagnostics Technology (GlobeNewswire)
Aug-12-24 04:10PM	Oncocyte's VitaGraft Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study (GlobeNewswire) -5.13%
Aug-08-24 04:05PM	Oncocyte Announces Successful GraftAssure Beta Launch and Q2 2024 Results (GlobeNewswire)
Aug-05-24 04:05PM	Oncocyte Announces August Investor Conferences Participation (GlobeNewswire) +6.27%
Aug-01-24 04:05PM	Oncocyte to Announce Second Quarter 2024 Financial Results on August 8 (GlobeNewswire) -5.14%
08:00AM	Loading…
Jul-11-24 08:00AM	MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in 'Take Advantage of the Moment' Episode (GlobeNewswire)
Jun-24-24 12:41PM	Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move (GlobeNewswire) -6.36%
Jun-17-24 04:05PM	Oncocyte Appoints Andrea James as Chief Financial Officer (GlobeNewswire)
Jun-05-24 07:00AM	OncoCyte's Innovative Approach: Potential in Precision Diagnostics (News Direct)
Jun-03-24 02:13PM	Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte's VitaGraft Study (GlobeNewswire)
May-30-24 04:47PM	Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine (GlobeNewswire)
May-15-24 08:55PM	OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	Oncocyte Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-13-24 08:00AM	Oncocyte to Announce First Quarter 2024 Financial Results (GlobeNewswire)
May-07-24 09:19AM	PRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics Marketplace (GlobeNewswire)
10:52AM	Loading…
Apr-12-24 10:52AM	OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -8.60%
06:00AM	Oncocyte Reports Full Year 2023 Financial Results (GlobeNewswire)
Apr-11-24 09:46PM	Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
05:30PM	Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay (GlobeNewswire)
Apr-09-24 04:05PM	Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Jan-16-24 08:00AM	Oncocyte to Present at the Sequire Investor Summit in Puerto Rico (GlobeNewswire)
Dec-06-23 08:00AM	Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays (GlobeNewswire)
Nov-09-23 08:27AM	OncoCyte Corp (OCX) Reports Q3 2023 Financial Results with Key Product Launches on the Horizon (GuruFocus.com) +29.71%
07:00AM	Oncocyte Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-03-23 08:30AM	Oncocyte to Announce Third Quarter 2023 Financial Results (GlobeNewswire) +8.09%
Sep-18-23 08:00AM	Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier (ACCESSWIRE) +5.49%
Sep-06-23 08:00AM	Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (ACCESSWIRE)
Aug-28-23 08:30AM	Oncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage (ACCESSWIRE)
Aug-10-23 07:00AM	Oncocyte Reports Second Quarter 2023 Financial Results (ACCESSWIRE)
Aug-09-23 08:00AM	Oncocyte Regains Compliance With Nasdaq Listing Requirements (ACCESSWIRE)
08:30AM	Loading…
Aug-08-23 08:30AM	Oncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference (ACCESSWIRE) -5.29%
Aug-03-23 08:00AM	Oncocyte To Announce Second Quarter 2023 Financial Results (ACCESSWIRE)
Jul-25-23 09:08AM	VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients (GlobeNewswire)
Jul-24-23 01:35PM	Oncocyte Announces 1-For-20 Reverse Stock Split (GlobeNewswire) -9.57%
Jun-27-23 08:30AM	Oncocyte Begins Manufacturing Transplant Blood Test (GlobeNewswire)
Jun-01-23 04:15PM	Oncocyte Corporation to Present at the LD Micro Invitational XIII (Newsfile) +6.55%
May-11-23 08:00AM	Oncocyte Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-27-23 04:59PM	Oncocyte To Announce First Quarter 2023 Financial Results (GlobeNewswire) +9.86%
Apr-18-23 08:45AM	Oncocyte Presents New Data at AACR (GlobeNewswire)
Apr-12-23 04:15PM	Oncocyte Announces Reduction in Force (GlobeNewswire) -5.08%
Apr-07-23 08:24AM	Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer (GlobeNewswire)
Apr-03-23 08:00AM	Oncocyte Pricing of $13.86 Million Public Offering of Common Stock (GlobeNewswire) -10.41%
Mar-31-23 05:00PM	Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K (GlobeNewswire) +26.57%
Mar-29-23 04:01PM	Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call (GlobeNewswire) +5.52% -8.50%
Mar-15-23 04:01PM	Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -20.00% +51.50%
Mar-02-23 09:00AM	Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer (GlobeNewswire)
Feb-22-23 08:00AM	Oncocyte Completes Razor Genomics Transaction (GlobeNewswire)
Dec-16-22 08:19AM	Oncocyte cuts 40% of staff (MarketWatch) -21.95%
08:00AM	Oncocyte Announces Initiatives to Focus Corporate Strategy (GlobeNewswire)
Nov-30-22 06:05PM	Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors (GlobeNewswire)
06:00PM	Oncocyte Announces Executive Leadership Changes (GlobeNewswire)
Nov-10-22 04:30PM	Oncocyte Reports Third Quarter 2022 Financial Results (GlobeNewswire) -21.72%
Oct-27-22 04:01PM	Oncocyte to Announce Third Quarter 2022 Financial Results (GlobeNewswire) -13.50%
Oct-06-22 08:00AM	DetermaIO Clinical Test to be used in SWOG Cancer Research Network Biomarker Study for Breast Cancer (GlobeNewswire)
Sep-07-22 08:00AM	Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on DetermaRx to CMS (GlobeNewswire)
Aug-31-22 04:01PM	Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference (GlobeNewswire)
Aug-30-22 04:27PM	Oncocyte Announces Five-Year VA Contract for DetermaRx (GlobeNewswire) -6.93%
Aug-24-22 08:00AM	Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer (GlobeNewswire)
Aug-10-22 04:05PM	Oncocyte Reports Second Quarter 2022 Financial Results (GlobeNewswire) +10.57%
Aug-03-22 04:01PM	Oncocyte to Participate at Upcoming Investor Conferences (GlobeNewswire) +13.60%
Aug-01-22 11:33AM	The past year for OncoCyte (NASDAQ:OCX) investors has not been profitable (Simply Wall St.)
05:00AM	Oncocyte Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective July 28, 2022 (GlobeNewswire)
Jul-27-22 04:01PM	Oncocyte to Announce Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-13-22 08:00AM	Oncocyte Announces Market Entry and Early Adopter Program for Transplant Rejection Monitoring Business (GlobeNewswire) +5.75%
Jul-06-22 08:00AM	Oncocyte Presents DetermaIO Data in Podium Presentation at ESMO World Congress on Gastrointestinal Cancer 2022 (GlobeNewswire)
Jun-22-22 08:00AM	Oncocyte Hosting Key Opinion Webinar on the Role of DetermaIO and the Tumor Microenvironment in Clinical Practice (GlobeNewswire)
Jun-15-22 07:15AM	How Much Of OncoCyte Corporation (NASDAQ:OCX) Do Insiders Own? (Simply Wall St.)
May-26-22 05:00PM	Oncocyte Presents DetermaIO Data at ASCO 2022 Supporting the Tests Potential to Expand the Clinical Use of Immunotherapy (GlobeNewswire)
May-11-22 04:05PM	Oncocyte Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-05-22 08:00AM	Oncocyte Completes Validation of TheraSure Transplant Monitor Test (GlobeNewswire)
Apr-28-22 04:01PM	Oncocyte to Announce First Quarter 2022 Financial Results (GlobeNewswire)
Apr-27-22 04:30PM	Oncocyte to Present New Data at ASCO 2022 Underpinning Pan-Cancer Clinical Utility of DetermaIO (GlobeNewswire)
Apr-22-22 09:26AM	A number of insiders bought OncoCyte Corporation (NASDAQ:OCX) stock last year, which is great news for shareholders (Simply Wall St.)
Apr-13-22 10:01PM	Oncocyte Corporation Announces Pricing of Public Offering of Common Stock and Warrants (GlobeNewswire)
05:12PM	Oncocyte Corporation Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire)
05:10PM	Oncocyte Corporation Announces Pricing of Registered Direct Offering of 11,765 Shares of Series A Convertible Preferred Stock (GlobeNewswire)
Apr-11-22 08:00AM	Oncocyte Presents Confirmatory Data for DetermaIO at the American Association for Cancer Research Annual Meeting 2022 (GlobeNewswire)
Mar-28-22 08:00AM	Oncocyte to Present New Data Confirming Association of IO Score with Response to Immunotherapy Treatment for Bladder Cancer at the American Association for Cancer Research Annual Meeting 2022 (GlobeNewswire)
Mar-10-22 04:05PM	Oncocyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +7.69% -7.86%
Mar-01-22 04:05PM	Oncocyte to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday March 10 (GlobeNewswire)
Feb-21-22 07:26AM	Shareholders in OncoCyte (NASDAQ:OCX) have lost 78%, as stock drops 12% this past week (Simply Wall St.)
Feb-10-22 08:00AM	Oncocyte to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (GlobeNewswire)
Jan-18-22 04:05PM	Oncocyte Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific to Expand Access to Precision Oncology (GlobeNewswire) +15.87% -24.20%
Jan-06-22 09:43AM	What Type Of Shareholders Make Up OncoCyte Corporation's (NASDAQ:OCX) Share Registry? (Simply Wall St.)
Jan-04-22 08:00AM	Oncocyte Announces Peer-Reviewed Publication in Cancers Showing Utility of DetermaCNI Blood-Only Monitoring Test to Detect Recurrence Following Surgery in Epithelial Ovarian Cancer (GlobeNewswire)
Dec-09-21 06:00PM	Spotlight Poster Presentation at San Antonio Breast Cancer Symposium SABCS 2021 Shows Oncocytes DetermaIO Clinical Test Predicts Response to Immunotherapy in Triple Negative Breast Cancer (GlobeNewswire) -9.81% -6.28%
Dec-08-21 08:00AM	Oncocyte and Burning Rock Complete Technology Transfer Part Two and Prepare for Scaled Distribution of DetermaRx in China (GlobeNewswire) +10.42%
Dec-06-21 08:00AM	Oncocyte Corporation Hosting Business Update Call (GlobeNewswire)
Dec-02-21 08:00AM	Oncocyte to Present New Data on DetermaIO Clinical Test for Immunotherapy Response in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium 2021 (GlobeNewswire)
Nov-22-21 06:14AM	Is OncoCyte (NASDAQ:OCX) Using Too Much Debt? (Simply Wall St.) -5.43%
Nov-09-21 04:05PM	Oncocyte Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) -6.42%
Nov-04-21 08:00AM	Oncocyte Announces the Clinical Launch of DetermaIO Immunotherapy Response Prediction Test (GlobeNewswire)
Nov-02-21 03:02PM	Will OncoCyte (OCX) Report Negative Earnings Next Week? What You Should Know (Zacks)
Oct-27-21 08:00AM	Oncocyte Strengthens Transplant Intellectual Property Portfolio with US Patent Covering Digital PCR Technology for Early Detection of Organ Transplant Rejection (GlobeNewswire) -5.00%
Oct-26-21 04:05PM	Oncocyte to Report Third Quarter 2021 Financial Results on Tuesday, November 9th (GlobeNewswire)
Oct-08-21 09:46AM	A OncoCyte Corporation (NASDAQ:OCX) insider increased their holdings by 11% last year (Simply Wall St.)
Oct-07-21 08:00AM	Oncocyte Appoints Gisela A. Paulsen as Chief Operating Officer (GlobeNewswire)
Sep-30-21 08:00AM	Oncocyte Publishes Study Demonstrating Predictive Potential for DetermaIO® Test in Triple Negative Breast Cancer (GlobeNewswire)
Sep-20-21 11:35AM	Oncocyte Announces Oral Presentation of New Data on Its DetermaIO Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting (GlobeNewswire)
08:00AM	Oncocyte Hosting Two-Part Key Opinion Leader Event Series (GlobeNewswire)

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BROADWOOD PARTNERS, L.P.	10% Owner	Apr 11 '24	Buy	2.92	2,420,000	7,057,688	4,929,066	Apr 15 07:21 PM
Riggs Josh	CEO and President	Apr 11 '24	Buy	2.95	3,390	10,000	3,505	Apr 15 06:04 AM
Arno Andrew	Director	Apr 11 '24	Buy	2.95	33,898	99,999	69,054	Apr 15 06:02 AM

Open in Screener

LCTX

Lineage Cell Therapeutics Inc

Sep 06 • 04:00PM ET

0.8360

Dollar change -0.0350
Percentage change -4.02	%

Healthcare • Biotechnology • USA • AMEX

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

LCTX Lineage Cell Therapeutics Inc daily Stock Chart

Index	RUT	P/E	-	EPS (ttm)	-0.13	Insider Own	0.44%	Shs Outstand	188.84M	Perf Week	-4.65%
Market Cap	157.87M	Forward P/E	-	EPS next Y	-0.14	Insider Trans	2.53%	Shs Float	188.00M	Perf Month	-3.35%
Income	-24.19M	PEG	-	EPS next Q	-0.04	Inst Own	50.54%	Short Float	8.25%	Perf Quarter	-14.69%
Sales	6.19M	P/S	25.50	EPS this Y	-7.14%	Inst Trans	0.01%	Short Ratio	23.56	Perf Half Y	-26.02%
Book/sh	0.36	P/B	2.31	EPS next Y	-11.48%	ROA	-22.55%	Short Interest	15.51M	Perf Year	-38.07%
Cash/sh	0.20	P/C	4.10	EPS next 5Y	-	ROE	-34.32%	52W Range	0.77 - 1.61	Perf YTD	-23.30%
Dividend Est.	-	P/FCF	-	EPS past 5Y	19.25%	ROI	-34.49%	52W High	-48.07%	Beta	1.26
Dividend TTM	-	Quick Ratio	2.64	Sales past 5Y	119.78%	Gross Margin	80.04%	52W Low	9.07%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	2.64	EPS Y/Y TTM	-3.94%	Oper. Margin	-413.76%	RSI (14)	41.07	Volatility	6.59% 6.76%
Employees	75	Debt/Eq	0.04	Sales Y/Y TTM	-41.22%	Profit Margin	-391.00%	Recom	1.43	Target Price	5.00
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	0.33%	Payout	-	Rel Volume	0.57	Prev Close	0.87
Sales Surprise	49.28%	EPS Surprise	33.33%	Sales Q/Q	-56.34%	Earnings	Aug 08 AMC	Avg Volume	658.42K	Price	0.84
SMA20	-4.81%	SMA50	-11.00%	SMA200	-21.25%	Trades		Volume	376,589	Change	-4.02%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-20-24	Initiated	Craig Hallum	Buy	$4
Nov-02-22	Initiated	Robert W. Baird	Outperform	$5
Jun-14-22	Initiated	B. Riley Securities	Buy	$4
Aug-19-21	Initiated	Noble Capital Markets	Outperform	$8
Mar-31-21	Initiated	Cantor Fitzgerald	Overweight	$6

Aug-13-24 08:00AM	Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (Business Wire)
Aug-08-24 06:35PM	Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Aug-01-24 08:00AM	Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 (Business Wire) -6.40%
Jul-02-24 08:00AM	Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index (Business Wire)
08:00AM	Loading…
May-30-24 08:00AM	Lineage to Present at 2024 BIO International Convention (Business Wire) +6.32%
May-21-24 08:00AM	Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium (Business Wire)
May-10-24 04:40PM	Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2024 Earnings Call Transcript (Insider Monkey) -6.84%
03:49PM	Lineage Cell Therapeutics Q1 2024 Earnings: Aligns with EPS Projections Amidst Revenue Declines (GuruFocus.com)
02:09PM	Q1 2024 Lineage Cell Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-09-24 04:01PM	Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
May-06-24 08:00AM	OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit (Business Wire) +22.64%
May-02-24 08:00AM	Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024 (Business Wire) -7.08%
Apr-30-24 08:00AM	Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM) (Business Wire)
Apr-29-24 04:30PM	Lineage Announces Changes to Board of Directors (Business Wire)
12:13PM	Loading…
Apr-19-24 12:13PM	12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By (Insider Monkey)
Apr-01-24 08:00AM	Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development (Business Wire)
Mar-18-24 10:31AM	15 Best Anti-Aging Foods for Youthful Skin (Insider Monkey) -9.30%
08:00AM	Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium (Business Wire)
Mar-14-24 03:53PM	Billionaire Ken Fisher and Corporate Insiders Are Buying These 10 Stocks (Insider Monkey)
Mar-13-24 08:00AM	RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit (Business Wire)
Mar-11-24 08:00AM	RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting (Business Wire)
Mar-08-24 04:20PM	Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2023 Earnings Call Transcript (Insider Monkey) +15.04%
Mar-07-24 10:36PM	Lineage Cell Therapeutics Inc. Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
04:01PM	Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (Business Wire)
Feb-29-24 08:00AM	Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024 (Business Wire)
Feb-13-24 08:00AM	Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury (Business Wire) -5.56%
Feb-09-24 09:15AM	Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering (Business Wire)
Feb-06-24 09:15AM	Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering (Business Wire) +6.73%
Jan-16-24 08:00AM	RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS (Business Wire)
08:00AM	Loading…
Dec-18-23 08:00AM	Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury (Business Wire) +16.47%
Nov-11-23 04:02PM	3 Penny Stocks to Buy for the Next Bull Run (InvestorPlace)
Nov-10-23 02:13PM	Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2023 Earnings Call Transcript (Insider Monkey)
09:17AM	Q3 2023 Lineage Cell Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-09-23 04:01PM	Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Nov-01-23 08:00AM	Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023 (Business Wire)
Oct-24-23 08:00AM	RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting (Business Wire)
Oct-17-23 05:14PM	Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks (InvestorPlace)
Oct-11-23 08:00AM	Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells (Business Wire)
Oct-05-23 08:00AM	RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (Business Wire) +10.00%
Sep-19-23 08:00AM	Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023 (Business Wire)
Sep-13-23 08:00AM	RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress (Business Wire)
Sep-11-23 08:00AM	Lineage to Present at 2023 International Spinal Research Trust Network Meeting (Business Wire)
Sep-06-23 09:40AM	EXCLUSIVE: Cell Therapy Player Lineage Cell Therapeutics Starts Development Activities Under Licensing Pact With Eterna Therapeutics (Benzinga)
08:00AM	Lineage Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna Therapeutics (Business Wire)
Aug-29-23 08:00AM	Lineage to Present at Baird 2023 Global Healthcare Conference and H.C. Wainwright & Co. 25th Annual Global Investment Conference (Business Wire)
Aug-13-23 06:39AM	Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 09:43AM	Q2 2023 Lineage Cell Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 05:15PM	Lineage Cell (LCTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Lineage Cell Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Aug-09-23 08:50AM	Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Aug-08-23 06:40PM	U.S. Physical Therapy (USPH) Beats Q2 Earnings and Revenue Estimates (Zacks)
Aug-03-23 08:00AM	Lineage Cell Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023 (Business Wire)
Jul-24-23 08:00AM	Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer (Business Wire)
May-22-23 08:00AM	Lineage Cell Therapeutics Expected to Be Added to Russell 3000® Index (Business Wire)
May-16-23 12:02PM	Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-11-23 05:35PM	Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (Business Wire)
May-09-23 08:00AM	Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM) (Business Wire)
May-04-23 06:15PM	Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates (Zacks)
08:00AM	Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023 (Business Wire)
Apr-26-23 08:00AM	RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration (Business Wire)
Apr-18-23 08:00AM	Lineage to Present at 2023 AAPS National Biotechnology Conference (Business Wire)
Apr-10-23 07:57PM	3 Penny Stocks to Buy During Market Downturns (InvestorPlace)
Mar-30-23 08:00AM	Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium (Business Wire)
Mar-28-23 03:57PM	Top 10 Growth Stocks in Biotech (Insider Monkey)
Mar-20-23 08:00AM	RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit (Business Wire)
Mar-11-23 03:00AM	Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-10-23 06:33AM	Q4 2022 Lineage Cell Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-09-23 05:25PM	Lineage Cell (LCTX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (Business Wire)
Mar-06-23 08:00AM	RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D. (Business Wire)
Mar-02-23 09:55AM	EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023 (Business Wire)
Feb-22-23 09:46AM	EXCLUSIVE: Lineage Cell Inks Exclusive Agreement For Novel Cell-Based Therapies With Potential In Neurology (Benzinga)
08:00AM	Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications (Business Wire)
Feb-08-23 08:00AM	Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss (Business Wire)
Nov-29-22 08:00AM	Lineage to Present at BTIG Ophthalmology Day and the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference (Business Wire) +5.76%
Nov-28-22 08:00AM	Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (Business Wire)
Nov-17-22 12:00PM	What Makes Lineage Cell (LCTX) a New Buy Stock (Zacks) +10.69%
09:45AM	2 Strong Buy Penny Stocks That Could See 200% Gains (Or More) (TipRanks)
Nov-10-22 06:35PM	Lineage Cell (LCTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +6.40% +8.27%
04:05PM	Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Nov-08-22 05:45PM	Berkeley Lights, Inc. (BLI) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-03-22 08:00AM	Lineage Cell Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10, 2022 (Business Wire)
Oct-31-22 08:00AM	Lineage Cell Therapeutics Appoints Jill Howe as Chief Financial Officer (Business Wire) +9.52%
Oct-10-22 08:00AM	Lineage Announces Notice of Allowance of Two Patents Covering Processes for Manufacturing Allogeneic Oligodendrocyte Progenitor and Retinal Pigmented Epithelium Cells (Business Wire)
Oct-04-22 08:00AM	Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the Mesa (Business Wire) +7.02%
Oct-03-22 08:00AM	Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel (Business Wire)
07:41AM	EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility (Benzinga)
Sep-19-22 07:00AM	The Three Best Anti-Aging Stocks to Buy in September (InvestorPlace) -5.43%
Aug-15-22 08:00AM	Lineage to Present at H.C. Wainwright & Co. 2nd Annual Virtual Ophthalmology Conference (Business Wire)
Aug-12-22 09:30AM	10 Best One Dollar Stocks To Buy Now (Insider Monkey)
02:31AM	Lineage Cell Therapeutics, Inc. (LCTX) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-11-22 04:05PM	Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Aug-08-22 06:05PM	Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -8.19% -5.10%
Aug-04-22 08:00AM	Lineage Cell Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022 (Business Wire) +8.59%
Jul-14-22 08:45AM	10 Best Penny Stocks to Buy in July (Insider Monkey)
Jun-02-22 08:00AM	Lineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery Technology (Business Wire) +6.50%
May-16-22 10:25AM	Lineage Cell Therapeutics, Inc. (LCTX) Q1 2022 Earnings Call Transcript (Motley Fool)

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Howe Jill Ann	Chief Financial Officer	Aug 16 '24	Buy	0.89	10,500	9,345	10,500	Aug 19 06:24 PM
Culley Brian M	President and CEO	May 24 '24	Buy	1.05	10,000	10,500	154,842	May 28 09:11 AM
BAILEY DON M	Director	Feb 08 '24	Buy	1.04	96,155	100,001	158,801	Feb 08 07:00 PM
BROADWOOD PARTNERS, L.P.	Director	Feb 06 '24	Buy	1.04	6,730,770	7,000,001	41,666,255	Feb 08 06:58 PM
Jayasuriya Anula	Director	Dec 29 '23	Buy	1.09	10,000	10,900	10,000	Jan 02 07:08 PM

STAA

Staar Surgical Co.

OCX

Oncocyte Corporation

LCTX

Lineage Cell Therapeutics Inc

Upgrade your FINVIZ experience